<DOC>
	<DOCNO>NCT02263976</DOCNO>
	<brief_summary>Main study : To investigate safety , tolerability , pharmacodynamics ( PD ) pharmacokinetics ( PK ) BEA 2180 BR Sub-study ; To investigate whether treatment 36 μg tiotropium bromide able protect methacholine-induced bronchoconstriction compare baseline ( methacholine challenge screen ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamics Pharmacokinetics BEA 2180 BR Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Methacholine Chloride</mesh_term>
	<criteria>Healthy male volunteer base upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test No find deviate normal clinical relevance No evidence clinically relevant concomitant disease Age ≥ 30 Age ≤ 55 year Body Mass Index ( BMI ) ≥ 18.5 BMI &lt; 30 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator ( deputy ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Exclusion criterion specific study : Bronchial hyperreactivity demonstrate 45 % change SGaw cumulative methacholine concentration 10 mg/mL = 1 % Asthma bronchial hyperreactivity Allergic rhinitis ( hay fever ) Glaucoma Urinary tract obstruction Epilepsy History cardiovascular disease History peptic ulcer disease History thyroid disease</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>